Elevance Health, Inc. (ELV) is set to report fourth-quarter 2024 results on Jan. 23, 2024, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter’s earnings is currently pegged at $3.82 per share on revenues of $44.67 billion. See the Zacks Earnings Calendar to stay ahead of market-making news.The fourth-quarter earnings estimate remained stable over the past 30 days. However, the bottom-line projection indicates a year-over-year decline of 32%. The Zacks Consensus Estimate for ...

Wall Street analysts forecast that Elevance Health (ELV) will report quarterly earnings of $3.82 per share in its upcoming release, pointing to a year-over-year decline of 32%. It is anticipated that revenues will amount to $44.67 billion, exhibiting an increase of 5.2% compared to the year-ago quarter.The consensus EPS estimate for the quarter has been revised 0.1% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial ...

Elevance Health (NYSE: ELV ) is a health insurance juggernaut. It provides medical services to approximately 47 million members in the United States. The company seems to be in good financial shape. However, its stock has significantly outperformed the overall market (I am an engineer and an individual who is passionate about finance/stock investment. I hold a Ph.D. in engineering and have been involved in acoustics and noise research for the past years. I am interested in capital appreciation opportunities ...

U.S. health benefits company Elevance Health, Inc. (ELV) shares have declined 29.6% quarter to date, underperforming its industry and the S&P 500 Index. Closing at $366.48 on Thursday, near its 52-week low of $362.21, the company’s current share price seems an excellent opportunity to build a position in a renowned company. After all, you would much rather buy closer to the low than the high, right?Elevance Health, headquartered in Indianapolis, IN, has a market capitalization of $84.9 billion. Its peers, U ...

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Elevance Health Inc. (NASDAQ: ELV) to determine whether certain Elevance officers and directors violated securities laws and breached fiduciary duties to shareholders. Elevance is a healthcare company that supports consumers, families, and communities across the entire care journey. What Now: If you own shares of Elevance Health Inc. and have lost money in your investment, contact us for more information ab ...

Elevance Health (NYSE: ELV ) is one of the largest healthcare insurers in the US. During FY23, they had 45 million members and had served over 115 million people. They have enjoyed revenue growth of 9.1% over the past 10 years and 13.7% EPSWe use Cash Flow Returns On Investment based DCF valuation tools provided by our affiliate company, ROCGA Research.With over 20 years of experience in investment analysis, we are actively seeking out undervalued and quality companies.ROCGA Research is an online platform t ...

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Elevance Health, Inc. (NYSE: ELV) or any of its executive officers violated securities laws by misrepresenting or failing to timely disclose material information to investors. The investigation focuses on investors' losses and whether they may be recovered under federal securities laws. What if I purchased Elevance securities? If you purchased securities and suffered losses on your investmen ...

Elevance Health, Inc. (NYSE:ELV) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET Company Participants Mark Kaye - Executive VP & CFO Conference Call Participants A.J. Rice - UBS A.J. Rice I think we'll go ahead and kick off today. I'm A.J. Rice, the health care services analyst at UBS. Thanks, everybody, for coming out to our conference this year. We're very pleased to have to kick off our session Elevance Health and principal speaker is going to be Mark Kaye, Chief Financial Officer and Exec ...

Elevance Health, Inc.'s (ELV) shares have lost 20% in the past three months compared with the industry's 7.1% decline. It has also lagged the broader Zacks Medical sector's 3.7% decline and the S&P 500's 10.4% rise in the said time frame. It has a market cap of $95.8 billion. Closing at $425.39 in the last trading session, the stock of the health benefit company stands 25% below its 52- week high of $567.26. Image Source: Zacks Investment Research What's Weighing on Elevance Health's Performance? Elevance H ...

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether Elevance Health, Inc. (NYSE: ELV) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased Elevance securities? If you purchased securities and suffered losse ...